Performance evaluation of an automated electrochemiluminescent calcitonin (CT) immunoassay in diagnosis of medullary thyroid carcinoma

Schiettecatte, Johan; Strasser, Olivia; Anckaert, Ellen; Smitz, Johan

doi:10.1016/j.clinbiochem.2016.05.006

Cited by 7 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The second antibody, labeled with a ruthenium complex, is used for calcitonin detection. The automated ECLIA assay benefits from a shorter test time and broader measurement range, thereby enabling the prompt, accurate diagnosis of calcitonin-related diseases (54,56).…”

Section: Methodsmentioning

confidence: 99%

ENDOCRINE TUMOURS: Calcitonin in thyroid and extra-thyroid neuroendocrine neoplasms: the two-faced Janus

Giannetta

Guarnotta

Altieri

et al. 2020

European Journal of Endocrinology

View full text Add to dashboard Cite

An increased calcitonin serum level is suggestive of a medullary thyroid cancer (MTC), but is not pathognomonic. The possibility of false positives or other calcitonin-secreting neuroendocrine neoplasms (NENs) should be considered. Serum calcitonin levels are generally assessed by immunoradiometric and chemiluminescent assays with high sensitivity and specificity; however, slightly-moderately elevated levels could be attributable to various confounding factors. Calcitonin values >100 pg/mL are strongly suspicious of malignancy, whereas in patients with moderately elevated values (10-100 pg/mL) a stimulation test may be applied to improve diagnostic accuracy. Although the standard protocol and the best gender-specific cut-offs for calcium stimulated calcitonin are still controversial, the fold of the calcitonin increase after stimulation seems to be more reliable. Patients with MTC show stimulated calcitonin values at least 3-4 times higher than the basal values, whereas calcitonin-secreting NENs can be distinguished from a C-cell disease by the absence of or <2-fold response to stimulation. The measurement of calcitonin in fine-needle aspirate washout (FNA-CT) and calcitonin immunocytochemical staining from thyroid nodules are ancillary methods that may significantly improve MTC diagnosis. The present review examines the gray areas in the interpretation of calcitonin measurement in order to provide a tool to clarify the origin of calcitonin secretion and differentiate the behavior of the two-faced Janus of neuroendocrinology: intra-thyroid (MTC) and extra-thyroid NENs.

show abstract

Section: Methodsmentioning

confidence: 99%

ENDOCRINE TUMOURS: Calcitonin in thyroid and extra-thyroid neuroendocrine neoplasms: the two-faced Janus

Giannetta

Guarnotta

Altieri

et al. 2020

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Accordingly, Lim and colleagues demonstrated a 98-99% negative predictive value for pathologically increased CT levels [20]. Recently, a new CT immunoassay become available on automated Cobas® platforms (Roche Diagnostic, Rotkreuz, Switzerland) [21,22] making feasible both simultaneous and sequential (reflex) measurement of CT and/or PCT on the same platform. Therefore, the present study was undertaken to compare the clinical performance of the automated Elecsys® CT and PCT assays and their combination or sequential use for the diagnosis of MTC.…”

Section: Introductionmentioning

confidence: 99%

Clinical performance of calcitonin and procalcitonin Elecsys^® immunoassays in patients with medullary thyroid carcinoma

Giovanella

Fontana

Keller

et al. 2020

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

ObjectivesMedullary thyroid carcinoma (MTC) is caused by a malignant transformation in the parafollicular C-cells of the thyroid, where calcitonin (CT) is released. Nowadays, CT is the main tumor marker used in the diagnosis and follow-up of MTC patients. Nonetheless, procalcitonin (PCT) has recently been proposed as a useful complementary/alternative biomarker in MTC. Our aims were to investigate the diagnostic performance of CT and PCT and their combination in the differential diagnosis between active and inactive MTC and between MTC and non-MTC thyroid diseases, respectively.MethodsSerum samples were collected from 16 patients with active (i.e. primary tumour before surgery or post-surgical recurrent disease) and 23 with inactive (i.e. complete remission) MTC, 125 patients with non-MTC benign thyroid disease and 62 patients with non-MTC thyroid cancers, respectively. Elecsys® CT and PCT measurements were simultaneously performed on the Cobas e601 platform (Roche Diagnostics, Rotkreutz, Switzerland).ResultsBoth CT and PCT median values in active MTC (94 pmol/L and 1.17 ng/mL, respectively) were significantly higher compared with inactive MTC (0.28 and 0.06) and either benign (0.37 and 0.06) or malignant (0.28 and 0.06) non-MTC. Undetectable PCT was found in five non-MTC patients with false positive CT results.ConclusionsElecsys® PCT assay is a highly sensitive and specific alternative MTC marker. At the very least it appears useful in patients with positive CT results as negative PCT values securely exclude active MTC. The availability of both markers on the same automated platform facilitates reflex or reflective strategies to refine the laboratory diagnosis.

show abstract

“…In normal endocrine processes, calcitonin inhibits calcium reabsorption from the bones, thereby main-임상적 중요 농도에서의 동등성 평가를 위한 세 가지 칼시토닌 자동 면역검사의 비교 cancer [6,[15][16][17][18][19]. Serum calcitonin concentration testing, like most tests conducted in modern clinical laboratories, is becoming increasingly advanced and automated [5,9,[20][21][22].…”

Section: Introductionmentioning

confidence: 99%

Comparison of Three Automated Calcitonin Immunoassays for Evaluating the Equivalence Near the Clinical Decision Point

2021

View full text Add to dashboard Cite

taining bone strength [1,2]. The plasma calcitonin concentration is relatively high in infants, and decreases rapidly until adolescence, leveling off during adulthood [3]. On average, its concentration is higher in men than in women [4,5]. Calcitonin concentration abnormally increases in medullarythyroid cancer [6,7]. A cut-off concentration of 10 pg/mL is most commonly used to differentiate between C-cell hyperactivity diseases (including medullary thyroid cancer) and other thyroid diseases [8-10]. In addition, a follow-up of plasma calcitonin concentration after treatment for medullary thyroid cancer is useful for monitoring recurrence and predicting patient prognosis [11,12].The diagnostic utility of plasma calcitonin concentration further increases when reviewed in combination with the carcinoembryonic antigen (CEA) concentration, RET protooncogene mutations, and needle aspiration biopsy ndings [13,14]. The measurement of serum calcitonin level is markedly signi cant as it serves as a quick and cost-effective method for diagnosing medullary thyroid

show abstract

Performance evaluation of an automated electrochemiluminescent calcitonin (CT) immunoassay in diagnosis of medullary thyroid carcinoma

Cited by 7 publications

References 8 publications

ENDOCRINE TUMOURS: Calcitonin in thyroid and extra-thyroid neuroendocrine neoplasms: the two-faced Janus

ENDOCRINE TUMOURS: Calcitonin in thyroid and extra-thyroid neuroendocrine neoplasms: the two-faced Janus

Clinical performance of calcitonin and procalcitonin Elecsys^® immunoassays in patients with medullary thyroid carcinoma

Comparison of Three Automated Calcitonin Immunoassays for Evaluating the Equivalence Near the Clinical Decision Point

Contact Info

Product

Resources

About

Performance evaluation of an automated electrochemiluminescent calcitonin (CT) immunoassay in diagnosis of medullary thyroid carcinoma

Cited by 7 publications

References 8 publications

ENDOCRINE TUMOURS: Calcitonin in thyroid and extra-thyroid neuroendocrine neoplasms: the two-faced Janus

ENDOCRINE TUMOURS: Calcitonin in thyroid and extra-thyroid neuroendocrine neoplasms: the two-faced Janus

Clinical performance of calcitonin and procalcitonin Elecsys® immunoassays in patients with medullary thyroid carcinoma

Comparison of Three Automated Calcitonin Immunoassays for Evaluating the Equivalence Near the Clinical Decision Point

Contact Info

Product

Resources

About

Clinical performance of calcitonin and procalcitonin Elecsys^® immunoassays in patients with medullary thyroid carcinoma